AgPlus Diagnostics is pleased to announce that the first functional prototype of the handheld AgPlus Diagnostics analytical platform is now fully operational and available for demonstration. Delivering laboratory-grade, quantifiable results within just 10 minutes of sample application, the portable AgPlus technology system has enormous potential in a wide variety of applications where a rapid, accurate and sensitive result is important for fast and reliable decision making.
The AgPlus Diagnostics platform utilizes electrochemical immunoassay technology in a patented microfluidic chip format. The unique signaling and measurement system, based on the detection of amplified silver ions by anodic stripping voltammetry, allows extremely sensitive, accurate and quantifiable results to be obtained from a very small sample volume (50µl) within minutes. The system doesn’t rely on an optical-based detection method so sample preparation is not required, making it ideal for multiple sample types and for testing in a range of settings.
The first fully functional AgPlus technology prototype will demonstrate an assay for human Troponin I, a cardiac marker used in clinical settings. The AgPlus Troponin I assay is currently showing a dynamic range of .1ng/ml – 50ng/ml with CVs <20% in a non-optimized format with assay run times of 10 minutes In addition, AgPlus tests for cortisol and testosterone are currently in development, which will be of value in sports science applications for developing more tailored training plans for athletes and to help reduce chances of Over Training Syndrome. The technology has been developed so that it can be applied to new and established chemistries and the platform software is easily integrated into existing information management systems. AgPlus Diagnostics foresee further potential for this technology in human (clinical and non-clinical) and veterinary diagnostics, as well as in environmental and military applications.
“The first working AgPlus technology system prototype is an important milestone for AgPlus Diagnostics, demonstrating the successful coming together of this novel diagnostic assay and its unique analytical platform to achieve a fully functional, portable system that can deliver accuracy and sensitivity that’s on a par with laboratory analyzers,” comments Chief Executive Officer, Keith Page.
AgPlus Diagnostics is seeking to develop partnerships and licensing agreements with collaborators in a variety of applications and business sectors. For further information or to discuss potential development or product licensing opportunities for human health applications, contact Courtney Nicholson on +44 (0)7730 099901, and for animal health applications, contact Keith Page on +44 (0)1234 867100. Alternatively, visit the AgPlus Diagnostics website at www.agplusdiagnostics.com.